AstraZeneca PLC (AZN) Stock Price & Analysis
AstraZeneca PLC (AZN) closed at USD 172.57 on Thursday, October 22, 2026, up 2.45% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 172.57; the Oct 22, 2026 session ranged USD 169.32–173.91 on volume of 2,773,214 shares. Market capitalization is —, with a 52-week range of USD 153.41–212.71 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/AZN.md
Key facts (AZN)
- 3 of 80 tracked superinvestors hold AZN (13F, Q2 2026): 0 new, 1 added, 2 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $2.2M; 1 not under a Rule 10b5-1 plan ($2.2M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Insider open-market purchases, last ~7 months: 1 Form 4 filing, $3K; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 2.17 on a 1–5 scale) (12 analysts), mean target USD 206.66 (range 158–240).
- Total return with dividends: 1Y +4.5% vs S&P 500 +14.9%; 5Y +53.9% vs S&P 500 +80.3%.
- Next earnings: 2026-10-30, EPS estimate USD 1.15, revenue estimate $16.0B.
Superinvestors (SEC 13F-HR, Q2 2026) (AZN)
3 of 80 tracked investors hold AZN. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Sarah Ketterer | Causeway Capital Management | 18.97% | $1.75B | Added +26.1% |
| Polen Capital | Polen Capital Management | 0.03% | $3.5M | Reduced -28.5% |
| Dodge & Cox Funds | Dodge & Cox | 0.01% | $10.6M | Reduced -2.6% |
Insider sales (SEC Form 4, open-market, last ~7 months) (AZN)
0 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-05-20 | Sharma Mani | See Remarks | 11,893 | $2.2M | 38.2% | No | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Insider purchases (SEC Form 4, open-market, last ~7 months) (AZN)
1 purchase, $3K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-08-08 | Sharma Mani | See Remarks | 20 | $3K | 160.57 | Too little history (no open-market trades in 2023–2025) |
Analysts (AZN)
Consensus Buy (mean 2.17 on a 1–5 scale), 12 analysts; mean target USD 206.66 (low 158, high 240).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-24 | CICC | Initiated | Outperform | $198 |
Total return (dividends reinvested) (AZN)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +4.5% | +53.9% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +4.5% | +9.0% |
| Volatility (annualized) | 27.4% | 25.0% |
| Max drawdown | -25.4% (Feb 2026→Aug 2026) | -27.8% (Aug 2024→Nov 2024) |
AZN suppliers, customers and competitors (named in its 20-F)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Cellectis S.A. (CLLS) | “On 1 November 2023, AstraZeneca entered into an agreement with Cellectis S.A., a clinical-stage biotechnology company, to accelerate the development of next generation therapeutics in areas of high unmet medical need, including oncology, immunology and rare diseases.” |
Quoted from the company's 20-F filed Feb 24, 2026.
Companies that name AZN in their SEC reports
| Relationship to AZN | Company | Filing | Sentence |
|---|---|---|---|
| partner | Eikon Therapeutics, Inc. (EIKN) | 10-K Mar 30, 2026 | “At Veracyte, he led collaborations with companies such as Bayer AG, AstraZeneca plc, and Johnson & Johnson, Inc., and orchestrated multiple acquisitions.” |
| partner | Allarity Therapeutics, Inc. (ALLR) | 10-K Mar 30, 2026 | “There are many other companies that have commercialized and/or are developing such treatments for cancer including large pharmaceutical and biotechnology companies, such as AstraZeneca plc, Bristol-Myers Squibb Company ("BMS"), Merck, Pfizer in partnership with Merck KGaA, Regeneron Pharmaceuticals, Inc. in partnership with Sanofi Genzyme ("Sanofi") and Roche.” |
| partner | Cellectis S.A. (CLLS) | 20-F Mar 20, 2026 | “We present below the accounting treatment applied in the Consolidated Financial Statements concerning the collaboration and investment agreements entered into with AstraZeneca Holdings B.V. ("AZ Holdings") and AstraZeneca Ireland Limited ("AZ Ireland") and, together with AZ Holdings and their respective affiliates, "AstraZeneca".” |
| partner | BridgeBio Oncology Therapeutics, Inc. (BBOT) | 10-K Mar 5, 2026 | “There are many other companies that have commercialized and/or are developing such treatments for cancer including large pharmaceutical and biotechnology companies, such as AstraZeneca plc, Bristol-Myers Squibb Company, Merck, Pfizer in partnership with Merck KGaA, Regeneron Pharmaceuticals, Inc. in partnership with Sanofi Genzyme and Roche.” |
| partner | Nuvation Bio Inc. (NUVB) | 10-K Mar 2, 2026 | “There are many other companies that have commercialized and/or are developing such treatments for cancer including large pharmaceutical and biotechnology companies, such as AstraZeneca plc, Bristol-Myers Squibb Company ("BMS"), Eli Lilly, Merck, Novartis Pharmaceuticals Corporation ("Novartis"), Pfizer, Regeneron Pharmaceuticals, Inc. in partnership with Sanofi Genzyme ("Sanofi") and Roche.” |
| partner | COMPUGEN LTD (CGEN) | 20-F Mar 2, 2026 | “We currently have two therapeutic program-based partnership agreements in effect, one with AstraZeneca plc, or AstraZeneca, and the second” |
| partner | Arcus Biosciences, Inc. (RCUS) | 10-K Feb 25, 2026 | “There are many other companies that have commercialized and/or are developing oncology treatments for cancer including large pharmaceutical and biotechnology companies such as AstraZeneca, BeiGene, Ltd. ("BeiGene"), The Bristol-Myer Squibb Company ("Bristol-Myers Squibb"), GlaxoSmithKline plc ("GSK"), Merck, Novartis Inc. ("Novartis"), Pfizer Inc. ("Pfizer"), Regeneron Pharmaceuticals, Inc. ("Regeneron") in partne…” |
| partner | Merck & Co., Inc. (MRK) | 10-K Feb 24, 2026 | “(2) Being jointly developed and commercialized in a worldwide collaboration with AstraZeneca.” |
| partner | AMGEN INC (AMGN) | 10-K Feb 13, 2026 | “TEZSPIRE is being developed in collaboration with AstraZeneca.” |
| partner | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | 10-K Feb 12, 2026 | “Companies working on chemically synthesized siRNAs include but are not limited to ADARx Pharmaceuticals, Inc., or ADARx, Amgen Inc., Argo Biopharmaceutical Co., Ltd., or Argo, Aro Biotherapeutics, Arrowhead Pharmaceuticals, Inc., or Arrowhead, AstraZeneca plc, or AstraZeneca, Dyne Therapeutics, Inc., Eli Lilly and Company, GlaxoSmithKline plc, Novartis, Novo Nordisk A/S, or Novo Nordisk, SanegeneBio, Sarepta Thera…” |
AZN analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $1.15 | $1.17 | -1.8% | $16.00B | 1 |
| Next quarter (ends Dec 2026) | $1.61 | $1.30 | +23.2% | $16.66B | 1 |
| Current fiscal year (ends Dec 2026) | $10.05 | $7.64 | +31.6% | $63.29B | 3 |
| Next fiscal year (ends Dec 2027) | $11.34 | $8.78 | +29.3% | $67.38B | 3 |
Key Statistics (as of October 23, 2026 at 09:21 UTC)
| Price | USD 172.57 |
|---|---|
| Change | ▲ 2.45% (up) |
| Previous Close | USD 172.57 |
| Open | USD 172.57 |
| Day Range | USD 169.32 – 173.91 |
| 52-Week Range | USD 153.41 – 212.71 |
| Volume | 2,773,214 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (AZN)
Nexqual's technical model rates AZN "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 09:21 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 65.24 (neutral) |
| vs SMA50 | Above (USD 162.8) |
| MACD | 1.5 (positive) |
Analyst Ratings (AZN)
Wall Street analysts rate AZN "Buy" based on 12 analysts, with a mean price target of USD 206.66 (range USD 158–240), per Nexqual as of October 23, 2026 at 09:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 206.66 |
| High Target | USD 240 |
| Low Target | USD 158 |
| Buy / Hold / Sell | 9 / 2 / 1 |
Earnings (AZN)
| Next Earnings Date | 2026-10-30 |
|---|---|
| Revenue Estimate | $16.00B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 1.32 vs est 1.25 ▲ beat |
| 2026-03-31 | USD 1.29 vs est 1.27 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:21 UTC.
Financials & Fundamentals (AZN)
| Total Revenue | $61.37B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +6.40% |
| Gross Margin | +81.69% |
| Operating Margin | +23.46% |
| Profit Margin | +17.02% |
| ROE | +21.96% |
| Debt / Equity | 0.64 |
| Current Ratio | 0.89 |
| Total Cash | $4.97B |
| Total Debt | $32.35B |
Source: Nexqual, October 23, 2026 at 09:21 UTC.
Ownership (AZN)
| Insider Ownership | +0.05% |
|---|---|
| Institutional Ownership | +76.35% |
| Shares Outstanding | 1.55B |
| Float | 1.54B |
| Short % of Float | +0.17% |
Source: Nexqual, October 23, 2026 at 09:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AMGN | Amgen Inc. | USD 447.28 | ▲ 2.04% |
| NVS | Novartis AG | USD 156.27 | ▲ 1.52% |
| GILD | Gilead Sciences, Inc. | USD 157.19 | ▲ 2.36% |
| MRK | Merck & Company, Inc. | USD 147.24 | ▼ 1.76% |
| NVO | Novo Nordisk A/S | USD 39.43 | ▲ 0.95% |
| PFE | Pfizer, Inc. | USD 30.42 | ▲ 1.91% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt